Steven K. Galson net worth and biography

Steven Galson Biography and Net Worth

Dr. Galson was appointed to the Board in September 2021. Most recently, Dr. Galson served as the Senior Vice President, Research and Development at Amgen. Prior to joining Amgen in 2010, where he also led regulatory affairs, Dr. Galson spent more than 20 years in public service roles across the US Department of Health and Human Services, Department of Energy, Environmental Protection Agency, and Centers for Disease Control and Prevention. From 2001 to 2007, he progressed from Deputy Director to Acting Director to Director of the Center for Drug Evaluation and Research at the US Food and Drug Administration. From 2007 to 2009 he served as acting Surgeon General of the United States. Dr. Galson received a B.S. in biochemistry from the State University of New York at Stony Brook, an M.D. from the Mt. Sinai School of Medicine, and a master’s degree in public health from the Harvard School of Public Health.

What is Steven K. Galson's net worth?: The estimated net worth of Steven K. Galson is at least $350,031.29 as of May 13th, 2024. Dr. Galson owns 51,551 shares of BioCryst Pharmaceuticals stock worth more than $350,031 as of April 7th. This net worth evaluation does not reflect any other investments that Dr. Galson may own. Learn More about Steven K. Galson's net worth.
How do I contact Steven K. Galson?: The corporate mailing address for Dr. Galson and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at investorrelations@biocryst.com. Learn More on Steven K. Galson's contact information.
Has Steven K. Galson been buying or selling shares of BioCryst Pharmaceuticals?: Steven K. Galson has not been actively trading shares of BioCryst Pharmaceuticals in the last ninety days. Most recently, on Monday, May 13th, Steven K. Galson bought 21,940 shares of BioCryst Pharmaceuticals stock. The stock was acquired at an average cost of $5.49 per share, with a total value of $120,450.60. Following the completion of the transaction, the director now directly owns 51,551 shares of the company's stock, valued at $283,014.99. Learn More on Steven K. Galson's trading history.
Who are BioCryst Pharmaceuticals' active insiders?: BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Steve Aselage (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Steven Galson (Director), Nancy Hutson (Director), Alan Levin (Director), Amy McKee (Director), Vincent Milano (Director), Machelle Sanders (Director), William Sheridan (Insider), Jon Stonehouse (CEO), and Helen Thackray (Chief Research & Development Officer). Learn More on BioCryst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of BioCryst Pharmaceuticals?: During the last twelve months, BioCryst Pharmaceuticals insiders bought shares 6 times. They purchased a total of 103,601 shares worth more than $596,337.56. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 13,289 shares worth more than $82,486.00. The most recent insider tranaction occured on June, 24th when Director Amy E Mckee sold 8,600 shares worth more than $54,352.00. Insiders at BioCryst Pharmaceuticals own 4.8% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.
Information on this page was last updated on 6/24/2024.

Steven K. Galson Insider Trading History at BioCryst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/13/2024	Buy	21,940	$5.49	$120,450.60	51,551

Steven K. Galson Buying and Selling Activity at BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Today's Range

Now: $6.79

$6.43

$7.05

50 Day Range

MA: $8.14

$6.83

$9.39

2 Week Range

Now: $6.79

$4.03

$9.50

Volume

4,368,573 shs

Average Volume

2,784,867 shs

Market Capitalization

$1.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75